BioVector? H446-DDP Cisplatin-Resistant Human Small Cell Lung Cancer Cell Line / H446-DDP 人小細(xì)胞肺癌順鉑抗性耐藥特異性細(xì)胞株

一 產(chǎn)品基本信息與細(xì)胞生物學(xué)背景

• 細(xì)胞名稱：H446-DDP（亦書寫為 NCI-H446/DDP 或 H446/DDP）。

• 物種與組織來源：人類（Homo sapiens），源自一名患有小細(xì)胞肺癌（Small Cell Lung Cancer, SCLC）患者的胸水轉(zhuǎn)移灶（其親本細(xì)胞為 NCI-H446），經(jīng)體外長期接觸順鉑（Cisplatin/DDP）壓力誘導(dǎo)篩選建立的特異性獲得性耐藥亞系。

• 細(xì)胞系建立背景（耐藥株的衍生）：親本 NCI-H446 細(xì)胞系是國際上研究小細(xì)胞肺癌最經(jīng)典的模式細(xì)胞之一，屬于變異型（Variant type）SCLC，具有典型的神經(jīng)內(nèi)分泌特征。順鉑（DDP）作為一種廣譜的 DNA 交叉聯(lián)結(jié)劑，是臨床治療小細(xì)胞肺癌聯(lián)合化療方案（如 EP 方案：依托泊苷 + 順鉑）的絕對核心。然而，小細(xì)胞肺癌極易產(chǎn)生繼發(fā)性耐藥導(dǎo)致臨床治療失敗?？蒲腥藛T為了在體外模擬這種耐藥性的獲得，將親本 H446 細(xì)胞長期暴露于含有階梯遞增濃度順鉑的培養(yǎng)基中（Stepwise escalating drug selection method）。歷經(jīng)數(shù)月的生存壓力誘導(dǎo)篩選，最終促使抗性克隆存活，鎖定并成功建立了具備高穩(wěn)定順鉑耐藥表型的衍生亞系 H446-DDP。

• 核心表型與耐藥機(jī)理特征：

  • 形態(tài)學(xué)改變：貼壁與半懸浮混合生長（以貼壁為主）。在倒置顯微鏡下，H446-DDP 細(xì)胞維持了基本的上皮樣（Epithelial-like）或多角形形態(tài)，但相較于親本 H446 細(xì)胞，耐藥株細(xì)胞之間的黏附力發(fā)生改變，常表現(xiàn)為更為緊密的細(xì)胞團(tuán)塊貼壁生長，局部可見部分胞體增大、拉長，伴隨顯著的骨架重塑（部分克隆表現(xiàn)出上皮-間充質(zhì)轉(zhuǎn)化 EMT 樣外觀）。

  • 耐藥譜系表征：對順鉑（Cisplatin）表現(xiàn)出極強的抵抗性，其半抑制濃度（IC50）較親本 NCI-H446 細(xì)胞顯著飆升。由于順鉑耐藥的復(fù)雜性，該細(xì)胞通常對其他鉑類化療藥（如卡鉑、奧沙利鉑）具有明顯的交叉耐藥性（Cross-resistance）。

  • 核心耐藥分子機(jī)制：H446-DDP 細(xì)胞的抗性是由多因素協(xié)同介導(dǎo)的：

    1. DNA 損傷修復(fù)（DDR）能力增強：細(xì)胞內(nèi)部高度激活了核苷酸切除修復(fù)（NER）通路（如 ERCC1 高表達(dá)）和錯配修復(fù)（MMR）機(jī)制，能高效清除順鉑引發(fā)的 DNA-鉑內(nèi)加合物，阻斷 DNA 雙鏈斷裂（DSBs）。

    2. 解毒系統(tǒng)激活：細(xì)胞內(nèi)谷胱甘肽（GSH）水平及谷胱甘肽S-轉(zhuǎn)移酶（GSTs）活性上調(diào)，在順鉑攻擊 DNA 前將其鰲合中和。

    3. 藥物外排泵上調(diào)：銅轉(zhuǎn)運蛋白（如 CTR1 下調(diào)阻斷攝入，ATP7A/7B 上調(diào)加速外排）或多藥耐藥相關(guān)蛋白（MRP 系列）高度活化。

    4. 抗凋亡通路激活：Bcl-2 表達(dá)上調(diào)，p53 信號通路發(fā)生功能缺陷，逃逸順鉑誘導(dǎo)的細(xì)胞凋亡級聯(lián)反應(yīng)。

• 生物安全級別：1級（BSL-1）。

二 核心科研價值與轉(zhuǎn)化醫(yī)學(xué)應(yīng)用

H446-DDP 細(xì)胞系作為高度公認(rèn)的肺癌一線化療耐藥模式底盤，在轉(zhuǎn)化醫(yī)學(xué)研究中扮演著核心角色：

1. 小細(xì)胞肺癌（SCLC）鉑類耐藥逆轉(zhuǎn)劑（Sensitizers）的體外高通量篩選：H446-DDP 是尋找能打破順鉑耐藥的小分子靶向藥、中藥天然提取物、非編碼 RNA 或小干擾 RNA（siRNA）的標(biāo)準(zhǔn)靶板?？蒲腥藛T常以此評估聯(lián)合用藥（如聯(lián)用特定激酶抑制劑、重金屬螯合劑）是否能重新將該細(xì)胞阻滯于順鉑引發(fā)的細(xì)胞周期。

2. DNA 損傷修復(fù)（DDR）通路靶向抗癌新藥評價：由于其本身具備極強的 DNA 自我修復(fù)背景，該細(xì)胞被廣泛用作靶底，用來測試新型 ATR/ATM 抑制劑、PARP 抑制劑、CHK1/2 阻斷劑或 WEE1 抑制劑在鉑類耐藥狀態(tài)下的獨立或協(xié)同殺傷效能（利用“合成致死”策略打破耐藥）。

3. 小鼠順鉑耐藥異種移植模型構(gòu)建（Resistant CDX Models）：將 H446-DDP 細(xì)胞接種于免疫缺陷小鼠（如 BALB/c Nude 裸鼠、NOD-SCID 小鼠）皮下，能快速構(gòu)建穩(wěn)定的、高度模擬臨床晚期化療耐藥患者病理狀態(tài)的異種移植（CDX）體內(nèi)模型，用以定量評價候選抗癌新藥或聯(lián)合免疫治療在體內(nèi)的腫瘤生長抑制率（TGI）及藥代動力學(xué)（PK）表征。

三 實驗室細(xì)胞復(fù)蘇、常規(guī)培養(yǎng)、傳代與保存標(biāo)準(zhǔn)步驟

H446-DDP 細(xì)胞呈貼壁與抱團(tuán)半懸浮混合生長特征（通常貼壁較牢，但密度大時易形成抱團(tuán)小球）。在日常維護(hù)中，最大的控制核心是維持其耐藥表型的穩(wěn)定性。

1. 培養(yǎng)基配置與耐藥壓力維持

• 基礎(chǔ)培養(yǎng)基：RPMI-1640 基礎(chǔ)培養(yǎng)基。

• 維持期完全培養(yǎng)基配方（日常傳代）：RPMI-1640 基礎(chǔ)培養(yǎng)基 加 10% 優(yōu)質(zhì)胎牛血清（FBS） 加 1% 青霉素-滅菌雙抗。

• 耐藥壓力維持（關(guān)鍵質(zhì)量控制點）：

  • 在常規(guī)擴(kuò)增與日常傳代期間，通常需要在完全培養(yǎng)基中額外添加維持濃度的順鉑（Cisplatin）藥物（具體維持濃度需嚴(yán)格遵照隨貨細(xì)胞說明書或特定的耐藥指數(shù)，常規(guī)維持濃度通常在 1 μg/mL - 2 μg/mL 左右），以防止細(xì)胞在完全無藥的環(huán)境下由于逆向進(jìn)化而導(dǎo)致耐藥特征發(fā)生部分回歸或丟失。

  • 重要提示：在正式用于下游實驗（如 MTT/CCK-8 藥效檢測、Western Blot 蛋白檢測或小鼠體內(nèi)接種）前的 24 至 48 小時，必須將細(xì)胞更換為不含順鉑的常規(guī)完全培養(yǎng)基進(jìn)行洗脫（Washout），以徹底清除細(xì)胞內(nèi)外殘留的游離順鉑對實驗數(shù)據(jù)的背景干擾。

• 細(xì)胞解離液：0.25% Trypsin-0.02% EDTA 消化液。

• 環(huán)境參數(shù)：37 攝氏度，5% 二氧化碳，飽和濕度孵箱。

2. 冷凍細(xì)胞復(fù)蘇步驟

1. 提前在無菌生物安全柜中配制好干凈的 T25 培養(yǎng)瓶，注入 5 - 6 mL 預(yù)熱至 37 攝氏度的常規(guī)完全培養(yǎng)基（注意：復(fù)蘇第一代時，為了保證受損細(xì)胞的恢復(fù)與貼壁，切勿添加順鉑藥物）。

2. 從液氮罐中取出 H446-DDP 凍存管，立刻全量投入 37 攝氏度恒溫水浴箱中快速搖晃解凍，確保在 1 分鐘內(nèi)令管內(nèi)冰塊完全融化。

3. 用 75% 酒精噴灑凍存管外壁消毒，隨后移入生物安全柜內(nèi)。

4. 用無菌移液槍吸取融化的細(xì)胞懸液，緩慢滴加至盛有 4 mL 預(yù)熱常規(guī)完全培養(yǎng)基的 15 mL 離心管中，輕柔顛倒一次以稀釋冷凍保護(hù)劑（DMSO）。

5. 以 1000 rpm（約 200 g）離心 5 分鐘，小心吸除含有 DMSO 的上清液。

6. 加入 1 mL 新鮮常規(guī)完全培養(yǎng)基輕輕重懸細(xì)胞沉淀。(注：由于 H446 細(xì)胞體較小且傾向于抱團(tuán)，重懸時需使用 P1000 槍頭輕柔化開)。

7. 將細(xì)胞全量接種至準(zhǔn)備好的 T25 瓶中。前后輕柔十字晃動混勻，置于孵箱中。

8. 復(fù)蘇 24 小時后，在顯微鏡下常規(guī)觀察細(xì)胞貼壁狀態(tài)。全量更換一次新鮮常規(guī)培養(yǎng)基以清除死細(xì)胞碎屑。待細(xì)胞完全恢復(fù)對數(shù)生長狀態(tài)（通常復(fù)蘇 2-3 天后），在下一次傳代時再重新加入含維持劑量順鉑的完全培養(yǎng)基。

3. 日常貼壁常規(guī)傳代操作

• 傳代時機(jī)：當(dāng)細(xì)胞融合度達(dá)到 80% - 90% 時必須進(jìn)行傳代。由于小細(xì)胞肺癌細(xì)胞傾向于密集靠攏并形成抱團(tuán)堆疊，絕對不能允許其長滿至 100%。一旦極度過密，抱團(tuán)的細(xì)胞塊極易大面積成片自發(fā)脫落，導(dǎo)致下層貼壁細(xì)胞受損，且易引發(fā)耐藥表型漂移。

• 操作流程：

  1. 吸除舊培養(yǎng)基（若有較多未貼壁的健康懸浮胞團(tuán)，可收集離心回配，若絕大多數(shù)已貼壁則直接吸除）。使用無菌的、不含鈣鎂離子的 PBS 緩沖液輕輕漂洗細(xì)胞表面 1 - 2 次，徹底洗去血清。

  2. 加入適量 0.25% 胰酶消化液（T25 瓶常規(guī)加入 1 mL），搖晃使其全面覆蓋細(xì)胞層。置于 37 攝氏度孵箱中消化 2 - 4 分鐘。

  3. 在倒置顯微鏡下實時動態(tài)觀察。當(dāng)發(fā)現(xiàn)貼壁的細(xì)胞集團(tuán)邊緣變圓、胞間裂隙增大、輕敲瓶壁可見大部分細(xì)胞成片移動或滑落時，立刻加入 2 到 3 倍體積的含血清完全培養(yǎng)基以終止胰酶的消化反應(yīng)。

  4. 用移液槍在瓶壁輕輕吹打。由于耐藥株細(xì)胞黏附性較強且易抱團(tuán)，可適當(dāng)增加吹打次數(shù)，使成片的細(xì)胞團(tuán)剝離并盡可能打散形成均勻的細(xì)胞懸液。收集懸液入管，1000 rpm 離心 5 分鐘。

  5. 棄去上清，加入含維持劑量順鉑的完全培養(yǎng)基重懸。按照 1 比 3 至 1 比 5 的常規(guī)稀釋比例，接種至新的培養(yǎng)瓶中。

  6. 通常每 2 - 3 天傳代一次。為了防止其耐藥基因發(fā)生長期的體外非特異性變異，建議體外連續(xù)傳代代數(shù)嚴(yán)格控制在 15 代以內(nèi)，嚴(yán)禁無限制無限期連續(xù)往下傳代。

4. 細(xì)胞長期保存標(biāo)準(zhǔn)

• 凍存液配方：90% 優(yōu)質(zhì)完全培養(yǎng)基（無順鉑） 加 10% 分析級二甲基亞砜（DMSO）。

• 冷凍規(guī)范：

  1. 收集處于對數(shù)生長最旺盛期、健康指數(shù)高、密度在 80% 左右、形態(tài)結(jié)構(gòu)處于標(biāo)桿加藥維持狀態(tài)的 H446-DDP 細(xì)胞。

  2. 經(jīng)溫和消化、離心沉淀后，用配置好的無藥凍存液懸浮，調(diào)整細(xì)胞密度至 每毫升 1,500,000 到 2,500,000 個細(xì)胞。

  3. 分裝入無菌凍存管中，立刻移入標(biāo)準(zhǔn)程序降溫盒（如 Mr. Frosty），并置于 零下 80 攝氏度冰箱中過夜梯度降溫（遵循約每分鐘降溫 1 攝氏度的穩(wěn)態(tài)速率）。

  4. 次日，必須迅速將凍存管轉(zhuǎn)移入液氮罐（零下 196 攝氏度）長期鎖死保存。絕對禁止在 零下 80 攝氏度普通冰箱內(nèi)長期存放，以防長期的微小熱輻射導(dǎo)致細(xì)胞內(nèi)部冰晶重塑，嚴(yán)重破壞后續(xù)復(fù)蘇時的存活率與特殊的順鉑抵抗表型。

Part 2 English Section

I General Information and Cell Biological Background

• Cell Line Name: H446-DDP (Standardly cataloged as NCI-H446/DDP, or H446/DDP).

• Organism and Tissue Extraction Origin: Homo sapiens (human); derived from a pleural effusion metastatic site of a donor diagnosed with Small Cell Lung Cancer (SCLC). The parental reference lineage is NCI-H446, and this subline was engineered through chronic in vitro selection exposure to Cisplatn (DDP).

• Cell Line Establishment Background (Derivation of the Drug-Resistant Line):The parental NCI-H446 reference line represents one of the most prominent globally utilized models of variant-type small cell lung cancer, characterized by robust neuroendocrine features. Cisplatin (DDP)—a broad-spectrum DNA cross-linking agent—serves as the cornerstone chemotherapeutic backbone for SCLC intervention regimens (such as the standard Etoposide + Cisplatin [EP] protocol). However, clinical prognosis is severely bottlenecked by the rapid onset of acquired drug resistance. To recapitulate this adaptive pathway in vitro, investigators cultivated parental H446 lineages under an escalating chemical selection pressure matrix (Stepwise escalating drug selection method) spanning several months. Surviving drug-tolerant clones were systematically expanded and validated to yield H446-DDP, locking in a highly stable cisplatin-resistant phenotype.

• Core Morphological Phenotype and Resistance Machinery:

  • Morphological Form: Mixed adherent and semi-suspension growth (primarily adherent). Under inverted phase-contrast microscopy, H446-DDP preserves a basic epithelial-like or polygonal architecture. However, compared to parent cells, the resistant variants manifest altered paracellular adhesion dynamics, proliferating in tighter, condensed cellular clusters that tightly grip the plastic plane. Localized clones may show cell enlargement, elongation, and profound cytoskeleton remodeling (resembling an Epithelial-Mesenchymal Transition [EMT]-like status).

  • Resistance Profile Designation: Demonstrates profound tolerance to Cisplatin, manifesting a marked surge in its half-maximal inhibitory concentration (IC50) index compared to parental H446 matrices. Due to the multi-layered biology of cisplatin resistance, the line consistently displays cross-resistance to related platinum analogs, such as Carboplatin and Oxaliplatin.

  • Molecular Escape Cascades: The cell's resistance profile is governed by multiple synchronous defense nodes:

    1. Enhanced DNA Damage Repair (DDR) Capacity: Upregulation of the Nucleotide Excision Repair (NER) network (e.g., elevated ERCC1 expression) alongside modified Mismatch Repair (MMR) frameworks, allowing efficient excision of cisplatin-induced intra-strand DNA-platinum adducts and preventing downstream DNA Double-Strand Breaks (DSBs).

    2. Hyper-Activated Detoxification Cascades: Elevation of intracellular Glutathione (GSH) synthesis and Glutathione S-Transferase (GSTs) enzymatic kinetics, which scavenge and neutralize free cisplatin molecules before they can target the genomic structure.

    3. Modified Transporter Architecture: Downregulation of the copper influx transporter CTR1 (blocking drug entry) paired with upregulated expression of ATP7A/ATP7B efflux pumps or multidrug resistance-associated proteins (MRP family).

    4. Suppression of Apoptosis: Hyper-activation of survival networks, including Bcl-2 upregulation and functional defects in the p53 tumor-suppressor cascade, shielding cells from cisplatin-triggered apoptotic breakdown.

• Biosafety Matrix: Classified under Biosafety Level 1 (BSL-1) parameters.

II Strategic Research Value and Translational Fields

SCLC is known for its aggressive nature and rapid development of resistance. H446-DDP serves as an important tool for evaluating clinical evasion nodes and testing advanced preclinical drug modalities:

1. High-Throughput Screening of SCLC Platinum Chemoresistance Reversers:The line functions as a standardized screening platform to identify small-molecule targeted inhibitors, natural products, or small interfering RNAs (siRNAs) capable of breaking cisplatin resistance. It enables investigators to discover synergistic combinations that can restore conventional chemotherapeutic efficacy.

2. Evaluating Advanced DNA Damage Repair (DDR) Pathway Inhibitors:Given its strong DNA self-repair profile, H446-DDP is widely used to evaluate the cytotoxicity of novel anticancer agents exploiting "synthetic lethality" concepts. This includes testing ATR/ATM inhibitors, PARP inhibitors, CHK1/2 blockers, and WEE1 antagonists to bypass platinum resistance nodes.

3. Predictable In Vivo Tumor Modeling via CDX Interfacing:Inoculated subcutaneously into athymic nude, NOD-SCID, or advanced immunodeficient rodent recipients, H446-DDP establishes reproducible Cell Line-Derived Xenograft (CDX) solid tumor models. These systems accurately replicate the clinical presentation of advanced, chemoresistant SCLC patients, serving as a reliable framework for quantifying Tumor Growth Inhibition (TGI) rates and validating preclinical pharmacokinetic (PK) parameters.

III Laboratory Thawing, Cultivation, Passaging, and Cryopreservation Protocols

H446-DDP cells exhibit a mixture of adherent and clustered semi-suspension expansion traits. The primary metric of daily cultivation is maintaining the stability of the drug-resistant phenotype through strict adherence to drug-maintenance windows and subconfluent passaging controls.

1. Growth Medium & Chemo-Pressure Maintenance Protocols

• Basal Medium: Standard RPMI-1640 medium.

• Maintenance Complete Medium Formulation (Routine Passaging): Basal RPMI-1640 medium enriched with 10% premium Fetal Bovine Serum (FBS) and fortified with 1% Penicillin-Streptomycin dual antibiotics.

• Drug Maintenance Control Window (Critical Protocol):

  • To preserve resistance stability during routine maintenance and expansion, the complete growth medium must be spiked with a maintenance dose of Cisplatin (tailored strictly to specific lot parameters or clonal resistance indexes; conventional baseline maintenance typically ranges from 1 μg/mL to 2 μg/mL). Cultivating cells in a drug-free matrix for extended intervals risks gradual regression or loss of the resistant phenotype due to backward evolutionary adaptation.

  • Critical Operational Note: The maintenance medium must be evacuated and replaced with drug-free complete growth medium 24 to 48 hours prior to downstream functional assays (e.g., in vitro CCK-8/MTT cytotoxicity screens, Western blotting, or live animal CDX inoculation) to wash out residual intracellular and free cisplatin fractions, eliminating background chemical interference.

• Cell Dissociation Enzyme: Standard 0.25% Trypsin-0.02% EDTA solution.

• Environmental Cultivation Constants: Incubate at 37 degrees Celsius inside a humidified atmosphere charged with 5% Carbon Dioxide.

2. Cryovial Thawing and Recovery Sequence

1. Pre-warm a pristine T25 tissue culture flask filled with 5 - 6 mL of standard drug-free complete growth medium inside the Class II Biosafety Cabinet. (Note: Do not add cisplatin during initial recovery to shield fragile, post-thaw membranes from acute cytotoxic stress).

2. Retrieve the H446-DDP cryovial from liquid nitrogen storage and submerge it instantly into a 37 degrees Celsius constant-temperature water bath. Shake rapidly and continuously to secure absolute thawing within 60 seconds.

3. Decontaminate the exterior shell with 75% ethanol before transfer into the biosafety cabinet.

4. Using a sterile pipettor, smoothly extract the thawed suspension and deliver it dropwise into a 15 mL conical tube packed with 4 mL of pre-warmed drug-free complete medium, inverting gently once to equalize osmotic pressures.

5. Centrifuge the suspension at 1000 rpm (approximately 200 g) for 5 minutes at room temperature, then carefully decant the DMSO-laden supernatant.

6. Resuspend the cell pellet in 1 mL of fresh drug-free complete growth medium. Because H446 cells have small diameters and naturally aggregate, perform gentle pipetting with a P1000 tip to disperse clusters.

7. Transfer the entire volume into the prepared T25 flask, distribute evenly via a gentle cross-shake movement, and place in the incubator.

8. Inspect the adherent status approximately 24 hours post-thaw. Perform a complete medium change to remove non-adherent dead cell fragments. Once the cells regain robust log-phase division metrics (typically 2-3 days post-thaw), reintroduce the complete growth medium spiked with the maintenance dose of cisplatin at the next passage.

3. Routine Adherent Passaging Mechanics and Maintenance

• Confluency Control Window: Subculturing routines must be initiated when monolayers achieve an optimal 80% - 90% confluency scale. Because SCLC cells naturally grow in tight clusters, never allow H446-DDP sheets to achieve 100% full saturation. Overcrowding triggers massive cell mass detachment due to underlying localized nutrient depletion, leading to cell stress and phenotypic resistance drift.

• Passaging Execution Steps:

  1. Aspirate the spent growth matrix (if healthy non-adherent cell clusters are present, they can be harvested via centrifugation and re-pooled; otherwise, discard). Gently rinse the cell layer 1 - 2 times with sterile, calcium/magnesium-free PBS to remove all remaining serum proteins that could deactivate the trypsin.

  2. Administer a suitable volume of 0.25% Trypsin-EDTA enzyme (typically 1 mL for a T25 flask format), tilt the flask to ensure total monolayer coverage, and place inside the 37 degrees Celsius incubator for 2 - 4 minutes.

  3. Monitor cell detachment kinetics under an inverted microscope. As the adherent clusters round up, separate from neighbors, and slide upon firm physical tapping of the flask wall, immediately add 2 to 3 volumes of serum-fortified complete growth medium to arrest enzymatic cleavage.

  4. Gently pipette the solution against the flask walls to rinse down remaining cells. Due to the high mechanical stickiness and clumping tendency of resistant SCLC strains, perform systematic pipetting to dissociate aggregates into a single-cell suspension. Transfer the fluid into a conical tube and centrifuge at 1000 rpm for 5 minutes.

  5. Discard the supernatant, resuspend the cell pellet in fresh complete growth medium supplemented with the maintenance dose of cisplatin, and inoculate into new flasks utilizing standard split ratios of 1:3 to 1:5. Subculture every 2 - 3 days.

  6. To prevent unintended long-term genetic drift in vitro, it is highly recommended to restrict continuous cultivation to under 15 total passages from thaw.

4. Long-Term Cryopreservation Standards

• Cryoprotectant Preservation Matrix: 90% premium complete growth medium (without cisplatin) supplemented with 10% analytical-grade Dimethyl Sulfoxide (DMSO).

• Freezing Protocol Validation:

  1. Exclusively harvest healthy, log-phase cultures showing an optimal confluency of approximately 80% under standard maintenance drug conditions.

  2. Post-enzymatic treatment and centrifugation, adjust the cell concentration inside the formulated drug-free cryoprotectant matrix to a target range of 1,000,000 to 2,000,000 cells per milliliter.

  3. Dispense the suspension into sterile cryovials, insert them immediately into a controlled-rate freezing device (e.g., Mr. Frosty), and place into a minus 80 degrees Celsius freezer overnight to achieve steady gradient cooling (approximately 1 degree Celsius per minute).

  4. The following day, swiftly transfer the frozen cryovials into liquid nitrogen storage tanks (minus 196 degrees Celsius) for definitive long-term preservation. Do not store vials indefinitely inside a minus 80 degrees Celsius freezer; minor temperature oscillations can compromise post-thaw recovery rates and lead to the degradation of resistant traits.

BioVector NTCC質(zhì)粒載體菌株細(xì)胞蛋白抗體基因保藏中心

電話:400-800-2947

工作QQ/微信同號:1843439339

網(wǎng)址http://www.nedfriskphoto.com